olymvax

Chengdu Olymvax Biopharmaceuticals Inc. is a biopharmaceutical company specializing in the research, production, and sales of human vaccines. Established in 2009 with a registered capital of 405.265 million yuan, the company successfully listed on the STAR Market of the Shanghai Stock Exchange on June 8, 2021 (Stock Code: 688319). Since its inception, the company has been committed to providing safe, effective, and high-quality human vaccine products to consumers both in China and internationally. It currently holds 42 Chinese invention patents, 2 U.S. patents, and 1 European patent. These include upgraded versions of traditional vaccines developed to enhance people’s quality of life, which have broad market demand, as well as innovative vaccine products with significant future market potential that address unmet or urgent disease control and prevention needs.